Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty-six research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and nineteen have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $903.64.

A number of equities research analysts have recently weighed in on REGN shares. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $800.00 to $850.00 and gave the company a “neutral” rating in a research note on Monday, October 16th. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $915.00 to $914.00 and set an “overweight” rating for the company in a report on Friday, November 3rd. Piper Sandler raised their price objective on shares of Regeneron Pharmaceuticals from $885.00 to $895.00 and gave the company an “overweight” rating in a report on Friday, November 3rd. Bank of America raised their price objective on shares of Regeneron Pharmaceuticals from $665.00 to $680.00 in a report on Friday, September 29th. Finally, Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $847.00 to $837.00 and set a “sector perform” rating for the company in a report on Friday, November 3rd.

Check Out Our Latest Research Report on REGN

Insider Activity at Regeneron Pharmaceuticals

Want More Great Investing Ideas?

In related news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $783.91, for a total transaction of $783,910.00. Following the completion of the transaction, the executive vice president now owns 19,803 shares in the company, valued at $15,523,769.73. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $783.91, for a total transaction of $783,910.00. Following the completion of the transaction, the executive vice president now owns 19,803 shares in the company, valued at $15,523,769.73. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $827.90, for a total value of $82,790.00. Following the transaction, the director now owns 18,547 shares of the company’s stock, valued at approximately $15,355,061.30. The disclosure for this sale can be found here. Insiders sold a total of 9,335 shares of company stock worth $7,791,203 over the last quarter. 8.83% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in REGN. NewSquare Capital LLC raised its holdings in Regeneron Pharmaceuticals by 1,450.0% in the first quarter. NewSquare Capital LLC now owns 31 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 29 shares in the last quarter. Sunbelt Securities Inc. bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $25,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at $26,000. Manchester Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 740.0% during the first quarter. Manchester Capital Management LLC now owns 42 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 37 shares in the last quarter. Finally, BerganKDV Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 444.4% during the second quarter. BerganKDV Wealth Management LLC now owns 49 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 40 shares in the last quarter. Institutional investors own 84.15% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.4 %

Shares of Regeneron Pharmaceuticals stock opened at $798.83 on Wednesday. The company has a market capitalization of $87.03 billion, a price-to-earnings ratio of 22.78, a PEG ratio of 3.00 and a beta of 0.13. The company has a quick ratio of 4.47, a current ratio of 5.18 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals has a 12-month low of $668.00 and a 12-month high of $853.97. The firm’s 50-day moving average price is $816.20 and its two-hundred day moving average price is $782.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $11.59 earnings per share for the quarter, beating analysts’ consensus estimates of $9.58 by $2.01. Regeneron Pharmaceuticals had a net margin of 30.47% and a return on equity of 18.61%. The company had revenue of $3.36 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same period last year, the company posted $9.98 EPS. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals will post 35.55 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

(Get Free Report

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.